Aldeyra Therapeutics Announces Positive Results from Dry Eye Disease Phase 2a Clinical Trial
Statistically and Clinically Significant Improvement Across Multiple Sign and Symptom Endpoints
Onset of Action Observed Within One Week of Therapy
Phase 2b Clinical Trial Expected to be Initiated in the First Half of 2018
LEXINGTON, Mass., Sept. 12, 2017 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced positive results from a Phase 2a clinical trial of topical ocular ADX-102 in patients with dry eye disease.
Read more: Aldeyra Therapeutics ( ALDX )
Published: 12 September 2017
Written by Editor